Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns

An Open, Non-comparative, Multi-center Investigation to Evaluate Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns

This a multi-center, open label, non-comparative, study that will evaluate the clinical safety and performance of Exufiber Ag+ and Exufiber dressings, separately, when used as intended in moderate to high exuding partial thickness burns (PTBs) through assessment of wound progression from baseline to the Subject's last clinical follow-up visit.

Sixty-eight (68) eligible subjects, with moderate to high exuding partial-thickness burns, will be selected for treatment with either Exufiber Ag+ silver-coated gelling dressing, or Exufiber gelling dressing. The study will last 5 weeks, with a requirement of 5 study visits in total, including dressing changes at each study visit.

Study Overview

• Status: Recruiting
• Conditions: Partial-thickness Burn
• Intervention / Treatment: Device: Exufiber; Device: Exufiber Ag+

Detailed Description

This is a multi-center study taking place in the United States, and conducted at 3-4 sites/locations. It is designed as an open, non-comparative study to test the safety and performance of Exufiber Ag+ and Exufiber in managing burn healing.

The primary objective of this study is to evaluate the clinical safety and performance of all study dressings, separately, when used as intended in moderate to high exuding partial thickness burns (PTBs) through assessment of wound progression from baseline to the Subject's last clinical follow-up visit. The dressings are intended to promote healing through the management of the wound environment.

Sixty-eight (68) subjects with partial thickness burns will be treated with either Exufiber Ag+ (34 subjects) or Exufiber (34 subjects) primary dressings, at the discretion of the Investigator. Secondary dressings should be non-adherent, non-antimicrobial dressings (local treatment praxis).

Each Subject will be evaluated at five (5) planned study visits for a maximum total treatment period of up to 21 days, unless the burn heals.

Visit 1 is a baseline visit to enroll Subjects and determine burn extent. Each Subject will be assigned to either Exufiber Ag+ or Exufiber primary dressings and treated according to the Instructions for Use (IFU) and the local clinical routine.

Visit 2 is a Confirmation Visit at up to 3 days, where the Investigator will confirm the burn meets study eligibility, and has not progressed to a full-thickness burn.

Visits 3, 4, and 5 are follow-up visits at days 7, 14, and 21, respectively, from the date of the primary dressing application.

At each follow-up visit the Subject will return to the clinic for evaluation and primary dressing change. Wound progression will be determined by the Investigator at each study visit and measured by three outcome variables (Deteriorated, No Change, Improved). Images of the wound at each follow up visit will be analyzed to determine changes in wound size.

Secondary endpoints will be collected identically at each visit at each clinical site to assess safety and performance of the dressings. The secondary objectives are:

• To evaluate time to discontinuation of study dressings from baseline to the last clinical follow-up visit, up to 21 days.
• To evaluate clinical outcomes of the study wound from baseline to the last clinical visit up to 21 days.
• To evaluate epithelization from baseline to the last clinical follow-up visit up to 21 days based on digital photo imaging software measurements.
• To evaluate a change in wound size from baseline to the last clinical follow-up visit up to 21 days based on digital photo and imaging software measurements.
• To evaluate healing status, including exudate levels, infection status, and proportion of burn healed, by clinician's visual judgement, at Confirmation Visit (up to 72 hours) and at each clinic follow-up visit, up to 21 days.
• To evaluate Subject-reported pain at application, during wear, and at dressing changes through questionnaires at each clinic follow-up visit up to 21 days.
• To evaluate treatment and dressing selections, including type and quantity, at application and at each clinic follow-up visit up to 21 days.
• To evaluate clinician handling of the dressing at application and at every dressing change performed at the clinic, from baseline and at each follow-up visit up to 21 days.
• To evaluate clinician assessment of the dressing at application and at every dressing change performed at the clinic, from baseline and at each follow-up visit up to 21 days.

• Study Type: Interventional
• Enrollment (Estimated): 68
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Jennifer O'Connell; Phone Number: +1 470 694-0750; Email: jennifer.oconnell@molnlycke.com

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19102
      • Recruiting
      • Drexel Univerisity
      • Contact: Paul Glat, MD
      • Principal Investigator: Paul Glat, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 weeks and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Signed informed consent
2. Burn of thermal origin
3. Patients presenting with partial thickness burns covering < 5% TBSA for study treatment
4. TBSA covered with any burn type is ≤15%, with a maximum of 10% being full thickness burns
5. Clean wounds with ≤10% necrotic tissue
6. Patients presenting with moderate to high exuding wounds
7. Serous or Serosanguinous exudate
8. Patient is not contraindicated for the dressing to which he/she is assigned

Exclusion Criteria:

1. Electrical Burns
2. Chemical Burns including acidic or basic sources
3. Ionizing radiation injuries
4. Dry wounds
5. Neonates
6. Patients with delayed presentation for burn care (>72 hours from time of injury)
7. Before entry into the study, treatment to the study wound included an active agent that would confound study results, as determined by the Investigator
8. Burns under study treatment transitioning to full thickness, or deep partial thickness burns requiring surgical treatment
9. Clinically infected burn
10. Patients with insulin dependent diabetes mellitus
11. Patients treated with systemic glucocorticosteroids, except patients taking occasional doses or doses less than 10mg prednisolone per day or equivalent
12. Patients who have used immunosuppressive agents, radiation or chemotherapy within past 30 days
13. Known allergy/hypersensitivity to any of the components of the investigation products
14. History of comorbid conditions or diagnoses associated with higher risk of infection as determined by the Investigator
15. Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer, severe anemia)
16. Patients that are not expected to comply with the investigation due to physical and/or mental conditions
17. Pregnancy
18. Participation in other clinical investigation(s) within 1 month prior to start of the investigation
19. Previously enrolled in this investigation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Exufiber; Treatment with Exufiber gelling fiber dressing	Device: Exufiber; A sterile nonwoven wound dressing made from highly absorbent PVA fibers.
Experimental: Exufiber Ag+; Treatment with Exufiber Ag+ silver-coated, gelling fiber dressing	Device: Exufiber Ag+; A sterile nonwoven wound dressing made from highly absorbent PVA fibers, and coated with silver sulphate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Wound progression	A subjective measurement to determine wound progression since the last visit, determined by three outcome variables: Deteriorated No Change Improved	5 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to discontinuation of study dressings	Measured by time (in days) from baseline to last clinical follow-up	5 weeks
Wound Size	Wound size (measured in inches or centimeters), at each study visit, from baseline to last clinical follow-up, using planimetry software to obtain measurements from digital photographs. Measurements to include length, width, and depth.	5 weeks
Re-epithelialization of wound	A measure of re-epithelization tissue, as a percentage of wound, from baseline to last clinical follow-up, using planimetry software to obtain measurements from digital photographs.	5 weeks
Wound Exudate	Evaluate the level of wound exudate, using the variables listed below: Dry Moist Wet Saturated Leaking	5 weeks
Wound Maceration	Determine the presence of wound maceration, using the variables listed below: Yes No	5 weeks
Proportion of Burn Healed	Evaluate the proportion of the burn that is healed, by clinician judgement, using the variables listed below: No healing 0-30% healed 31-70% healed 71-99% healed 100% healed	5 weeks
Blistering	Determine the presence of wound blistering, using the variables listed below: Yes No	5 weeks
Wound Redness/Irritation peri-wound skin	Determine the presence of redness and irritation on the peri-wound skin, using the variables listed below: Yes No	5 weeks
Exudate Nature	Determine the nature of wound exudate, using the variables listed below: Serous Serosanguinous Sanguineous Purulent	5 weeks
Malodor	Determine the presence of wound malodor, using the variables listed below: None Slight Moderate Strong	5 weeks
Burn odor	Determine the presence of burn odor, using the variables listed below: Yes No	5 weeks
Local infection	Determine the presence of signs of local wound infection, using the variables listed below: New / Increasing Pain Delayed / Stalled Healing Purulent discharge Erythema Local Warmth Exudation Odor Pyrexia Induration Leukocytosis Edema / Swelling Eschar	5 weeks
Subject pain	Measured at dressing application, change, and removal, using a patient reported outcome questionnaire that is used to evaluate pain intensity on a validated scale from 0-10. A higher score correlates with greater experienced pain.	5 weeks
Dressing Adherence	Subjective measurement to asses performance of the primary dressing and its adherence to the wound bed, using the variables listed below: Yes No	5 weeks
Rewetting	Subjective measurement to asses performance of the primary dressing and the need for re-wetting prior to removal, using the variables listed below: Yes No	5 weeks
Dressing ability to rehydrate	Subjective measurement to asses performance of the primary dressing and its ability to rehydrate the wound, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Dressing ability to retain exudate	Subjective measurement to asses performance of the primary dressing and its ability to retain wound exudate, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Dressing ability to absorb blood	Subjective measurement to asses performance of the primary dressing and its ability to absorb blood, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Dressing ability to retain slough	Subjective measurement to asses performance of the primary dressing and its ability to retain slough, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Dressing ability to clean wound bed	Subjective measurement to asses performance of the primary dressing and its ability to clean the wound bed, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Dressing ability to retain gelling properties	Subjective measurement to asses performance of the primary dressing and its ability to retain its gelling properties, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Dressing ability to retain balanced moist environment	Subjective measurement to asses performance of the primary dressing and its ability to retain a balanced moist environment, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Dressing conformability	Subjective measurement to assess performance of the primary dressing and its ability to conform, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Dressing flexibility	Subjective measurements to assess performance of the primary dressing and its flexibility, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Ease of dressing application	Subjective measurement to assess the handling of the primary dressing and ease of dressing application, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Ease of dressing removal with and without moistening	Subjective measurement to assess the handling of the primary dressing and ease of removal with and without moistening, using the variables listed below: Very poor Poor Good Very good N/A	5 weeks
Dressing removal in one piece	Subjective measurement to assess the handling of primary dressing and its ability to be removed in one piece, using the variables listed below: Yes No	5 weeks
Residuals of dressing material in the wound or surrounding skin	Subjective measurement to assess presence of primary dressing residuals in the wound or surrounding skin at the time of removal, using the variables listed below: Yes No	5 weeks
Bleeding at removal	Subjective measurement to assess presence of bleeding at the time of primary dressing removal, using the variables listed below: Yes No	5 weeks

Collaborators and Investigators

• Sponsor: Molnlycke Health Care AB

Study record dates

Study Major Dates

• Study Start (Actual): March 10, 2021
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: April 5, 2021
• First Submitted That Met QC Criteria: April 7, 2021
• First Posted (Actual): April 9, 2021

Study Record Updates

• Last Update Posted (Actual): October 19, 2023
• Last Update Submitted That Met QC Criteria: October 18, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Wounds and Injuries; Burns
• Other Study ID Numbers: PTB01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No